Profile: Insmed Inc (INSM.O)
22 May 2019
Insmed Incorporated, incorporated on March 21, 2013, is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its earlier-stage clinical pipeline includes INS1007 and INS1009.
The Company’s product ARIKAYCE is for the treatment of refractory MAC lung disease. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. ARIKAYCE is administered once-daily using Lamira. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and is designed specifically for ARIKAYCE delivery.
INS1007 is an novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow.
INS1009 is an inhaled treprostinil prodrug. INS1009 offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).
10 Finderne Ave Bldg 10
BRIDGEWATER NJ 08807-3365